Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 10, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13045-017-0519-7
Keywords
Chimeric antigen receptors; Acute myeloid leukemia; Immunotherapy
Categories
Funding
- National Basic Research Program of China [2013CB932500]
- National Natural Science Foundation of China [60976004]
- 985 grants of East China Normal University (ECNU)
Ask authors/readers for more resources
Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapies against B-lineage malignancies, many studies have attempted to translate the success of CAR T cell therapy to other malignancies, including AML. This review summarizes the current advances in CAR T cell therapy against AML, including preclinical studies and clinical trials, and discusses the potential AML-associated surface markers that could be used for further CAR technology. Finally, we describe strategies that might address the current issues of employing CAR T cell therapy in AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available